TIL on Nasdaq

Instil Bio, Inc.

We are a biotechnology company focused on identifying and advancing innovative therapeutic opportunities.⁵ From its latest annual report

$6.37 up 0.42 (7.06%)Price as of Oct 15, 2026 at 17:33 UTC

Last updated Oct 19, 2026.

Overview

Compare with VivoSim Labs, INC., Candel Therapeutics or Zivo Bioscience, Inc., or pick any stock.

TickerTIL on Nasdaq²
IndustryBiological Products, (No Diagnostic Substances)²
HeadquartersDover, United States²
Incorporated inNY⁴
Business address3963 Maple Avenue, Suite 350, Dallas, Tx 75219⁴
Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company⁴
Legal formCorporation²
LEI529900HW1XOEQEVG5T88²
StatusActive²
LEI statusIssued and current²
Registered addressc/o INCORPORATING SERVICES, LTD., 3500 S DUPONT HWY, 19901 Dover, United States²
Registered withDivision of Corporations, Department of State, 7039820²

See how the biggest companies compare on our leaderboards

We are a biotechnology company focused on identifying and advancing innovative therapeutic opportunities.⁵ From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-100.0%Revenue growth, 2021⁶

-28.2%Return on equity⁷

-$180.0MFree cash flow⁸

Financial statements

Revenue⁶$0 in 2021

Operating income⁶⁸-$155.6M in 2021+362% since 2020

Net income⁶⁸-$156.8M in 2021+315% since 2020

Every line of the income statement as filed: the last 2 fiscal years, latest first.¹¹

Period ending	2025-12-31	2024-12-31
In-process research and development	$10.0M	$10.0M
Research and development	$24.7M	$11.8M
General and administrative	$27.2M	$44.2M
Restructuring and impairment charges	$16.6M	$7.5M
Total operating expenses	$78.6M	$73.5M
Loss from operations	-$78.6M	-$73.5M
Interest income	$3.9M	$7.0M
Interest expense	-$5.8M	-$9.0M
Other rental income	$9.0M	$4.3M
Other income (expense), net	$212.0K	-$2.9M
Net loss	-$71.4M	-$74.1M
Foreign currency translation	-$342.0K	$168.0K
Unrealized loss on available-for-sale securities, net	-$13.0K	-$48.0K
Net comprehensive loss	-$71.7M	-$74.0M
Net loss per share, basic (in dollars per share)	-$10.70	-$11.39
Net loss per share, diluted (in dollars per share)	-$10.70	-$11.39
Weighted-average shares used in computing net loss per share, basic (in shares)	6.7M shares	6.5M shares
Weighted-average shares used in computing net loss per share, diluted (in shares)	6.7M shares	6.5M shares

Total assets⁶⁸$610.0M in 2021+91% since 2020

Total liabilities⁶⁸$54.8M in 2021+106% since 2020

Shareholders’ equity⁶⁸⁷$555.2M in 2021

Cash⁶⁸$37.6M in 2021+323% since 2019

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.¹¹

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$6.6M	$8.8M
Restricted cash	$166.0K	$1.8M
Marketable securities	$69.5M	$104.5M
Prepaid expenses and other current assets	$3.0M	$9.3M
Assets held for sale	$112.1M	$0
Total current assets	$191.4M	$124.5M
Property, plant and equipment, net	$126.0K	$129.4M
Operating lease right-of-use assets	$238.0K	$934.0K
Accrued rent receivable	$7.7M	$4.3M
Other long-term assets	$4.1M	$4.5M
Total assets	$203.5M	$263.6M
Accounts payable	$779.0K	$659.0K
Accrued expenses and other current liabilities	$4.1M	$7.2M
Total current liabilities	$4.8M	$7.9M
Contingent consideration	$0	$948.0K
Operating lease liabilities, non-current	$0	$1.0M
Loan payable	$84.8M	$84.2M
Other long-term liabilities	$8.0K	$83.0K
Total liabilities	$89.7M	$94.1M
Preferred stock, par value $0.000001 per share; 10,000,000 shares authorized; zero shares issued and outstanding as of December 31, 2025, and 2024	$0	$0
Common stock, par value $0.000001 per share; 300,000,000 shares authorized; 6,781,976 and 6,525,887 shares issued and outstanding as of December 31, 2025, and 2024	$0	$0
Additional paid-in capital	$840.9M	$824.8M
Accumulated other comprehensive loss	-$583.0K	-$228.0K
Accumulated deficit	-$726.5M	-$655.1M
Total stockholders equity	$113.9M	$169.4M	$225.8M
Total liabilities and stockholders equity	$203.5M	$263.6M
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock authorized (in shares)	10.0M shares	10.0M shares
Preferred stock issued (in shares)	0 shares	0 shares
Preferred stock outstanding (in shares)	0 shares	0 shares
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	300.0M shares	300.0M shares
Common stock, shares issued (in shares)	6.8M shares	6.5M shares
Common stock, shares outstanding (in shares)	6.8M shares	6.5M shares

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$6.6M	$8.8M
Restricted cash	$166.0K	$1.8M
Marketable securities	$69.5M	$104.5M
Prepaid expenses and other current assets	$3.0M	$9.3M
Assets held for sale	$112.1M	$0
Total current assets	$191.4M	$124.5M
Property, plant and equipment, net	$126.0K	$129.4M
Operating lease right-of-use assets	$238.0K	$934.0K
Accrued rent receivable	$7.7M	$4.3M
Other long-term assets	$4.1M	$4.5M
Total assets	$203.5M	$263.6M
Accounts payable	$779.0K	$659.0K
Accrued expenses and other current liabilities	$4.1M	$7.2M
Total current liabilities	$4.8M	$7.9M
Contingent consideration	$0	$948.0K
Operating lease liabilities, non-current	$0	$1.0M
Loan payable	$84.8M	$84.2M
Other long-term liabilities	$8.0K	$83.0K
Total liabilities	$89.7M	$94.1M
Preferred stock, par value $0.000001 per share; 10,000,000 shares authorized; zero shares issued and outstanding as of December 31, 2025, and 2024	$0	$0
Common stock, par value $0.000001 per share; 300,000,000 shares authorized; 6,781,976 and 6,525,887 shares issued and outstanding as of December 31, 2025, and 2024	$0	$0
Additional paid-in capital	$840.9M	$824.8M
Accumulated other comprehensive loss	-$583.0K	-$228.0K
Accumulated deficit	-$726.5M	-$655.1M
Total stockholders equity	$113.9M	$169.4M	$225.8M
Total liabilities and stockholders equity	$203.5M	$263.6M
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock authorized (in shares)	10.0M shares	10.0M shares
Preferred stock issued (in shares)	0 shares	0 shares
Preferred stock outstanding (in shares)	0 shares	0 shares
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	300.0M shares	300.0M shares
Common stock, shares issued (in shares)	6.8M shares	6.5M shares
Common stock, shares outstanding (in shares)	6.8M shares	6.5M shares

Cash from operations⁶⁸-$122.1M in 2021+312% since 2020

Capital spending⁶⁸$57.8M in 2021+14% since 2020

Free cash flow⁶⁸-$180.0M in 2021+124% since 2020

Every line of the cash flow as filed: the last 2 fiscal years, latest first.¹¹

Period ending	2025-12-31	2024-12-31
Net loss	-$71.4M	-$74.1M
Stock-based compensation	$8.7M	$17.3M
Non-cash lease expense	$286.0K	$212.0K
Foreign exchange remeasurement (gain) loss	-$484.0K	$275.0K
Impairment of property, plant and equipment	$16.6M	$4.3M
Impairment of right-of-use assets	$0	$827.0K
Change in fair value of contingent consideration	-$948.0K	-$3.9M
Depreciation	$534.0K	$3.6M
Restructuring costs	-$91.0K	$0
In-process research and development expenses	$10.0M	$10.0M
Accretion on invested securities	-$37.0K	-$4.3M
Non-cash interest expense	$791.0K	$962.0K
Non-cash loss on debt extinguishment	$0	$415.0K
Change in fair value of derivative financial instrument	$0	$1.1M
Loss on disposals of property and equipment	$0	$343.0K
Prepaid expenses and other current assets	$6.1M	-$221.0K
Other long-term assets	$425.0K	-$4.4M
Accrued rent receivable	-$3.4M	-$4.3M
Accounts payable	$116.0K	-$556.0K
Operating lease liabilities	-$1.4M	-$1.4M
Long-term liabilities	-$79.0K	$77.0K
Accrued expenses and other current liabilities	-$2.3M	-$1.9M
Net cash used in operating activities	-$36.6M	-$55.7M
Purchase of marketable securities	-$100.9M	-$134.0M
Maturities of marketable securities	$135.9M	$198.1M
Cash received from asset disposals	$432.0K	$866.0K
Acquired in-process research and development	-$10.0M	-$10.0M
Cash received from termination of derivative financial instrument	$0	$605.0K
Purchase of derivative financial instrument	$0	-$1.6M
Net cash provided by investing activities	$25.5M	$54.0M
Proceeds from the 2024 Loan	$0	$85.6M
Principal payments on Construction Loans	$0	-$82.8M
Proceeds from at-the-market offering, net of $0.3 million in issuance costs	$6.6M	$0
Proceeds from exercise of stock options	$853.0K	$365.0K
2024 Loan agreement closing costs	-$172.0K	-$1.4M
Net cash provided by financing activities	$7.3M	$1.8M
Net (decrease) increase in cash, cash equivalents, and restricted cash	-$3.9M	$33.0K
Effect of exchange rate changes on cash, cash equivalents and restricted cash	$20.0K	-$94.0K
Cash paid for interest	$5.0M	$8.0M

Compare Instil Bio, Inc. with another company

Leadership

Who has led Instil Bio, Inc., and when. Pick a name to see everywhere that person has worked.

2025

Chief executive officerBronson Crouch Mar 18, 2021 to now¹²
ChairBronson Crouch Mar 18, 2021 to now¹²
Chief financial officerSandeep Laumas Mar 18, 2021 to now¹³

Board members and other officers (8)

Chief Technical OfficerVijay Chiruvolu Mar 18, 2021 to May 25, 2022¹⁴
Chief Medical OfficerZachary Roberts Mar 18, 2021 to Mar 7, 2022¹⁵
Board memberGeorge Matcham Mar 18, 2021 to now¹⁶
Board memberGwendolyn Binder Mar 18, 2021 to now¹⁷
Board memberJack Nielsen Mar 18, 2021 to Jan 10, 2024¹⁸
Board memberNimish P. Shah Mar 18, 2021 to Mar 25, 2021¹⁹
Board memberR. Kent McGaughy Jr. Mar 18, 2021 to now²⁰
General counselSumita Ray May 3, 2022 to Jan 20, 2023²¹

Timeline

Mar 18, 2021New chief executive Bronson Crouch becomes CEO¹²
Aug 31, 2018Founded Instil Bio, Inc. is founded²

Filings

170 filings to the SEC since October 2021: 5 annual reports, 16 quarterly reports, 60 major events, 44 insider forms, 18 large holders, 27 other. The latest 20:

Aug 13, 202610-Q EDGAR
Aug 13, 20268-K EDGAR
Jun 12, 20264 EDGAR
Jun 12, 20264 EDGAR
Jun 12, 20264 EDGAR
Jun 12, 20264 EDGAR
Jun 11, 20268-K EDGAR
May 15, 202610-Q EDGAR
May 15, 20268-K EDGAR
Apr 24, 2026ARS EDGAR
Apr 24, 2026DEFA14A EDGAR
Apr 24, 2026DEF 14A EDGAR
Apr 3, 20268-K EDGAR
Mar 27, 202610-K EDGAR
Mar 27, 20268-K EDGAR
Mar 27, 2026S-8 EDGAR
Feb 9, 2026SCHEDULE 13G/A EDGAR
Jan 6, 20268-K EDGAR
Nov 13, 202510-Q EDGAR
Nov 13, 20258-K EDGAR

The 170 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

1 open-market trades by officers, directors and large owners since October 2021: 0 buys and 1 sales. Grants, option exercises and gifts are left out.

Date	Who	Trade	Shares	Price	Value	Filing
Sep 10, 2025	Laumas SandeepCFO and CBO	Sale	30,000	$23.39	$701.7K	Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

BML Investment Partners, L.P.SCHEDULE 13G/A, 3 filings Apr 2, 2024 to Feb 9, 2026²²
Vivo Capital IX, LLCSCHEDULE 13G/A, 2 filings Nov 14, 2024 to Aug 12, 2025²³
Boxer Capital Management, LLCSCHEDULE 13G/A, 2 filings Oct 25, 2024 to May 15, 2025²⁴
PERCEPTIVE ADVISORS LLCSCHEDULE 13G/A, 2 filings Sep 27, 2024 to May 15, 2025²⁵
Venrock Healthcare Capital Partners II, L.P.SC 13G/A, 1 filing Nov 14, 2024²⁶
Curative Ventures V LLCSC 13D/A, 1 filing Oct 22, 2024²⁷
Boxer Capital, LLCSC 13G, 1 filing Sep 27, 2024²⁸
FMR LLCSC 13G/A, 4 filings Nov 10, 2021 to Apr 10, 2023²⁹
RA CAPITAL MANAGEMENT, L.P.SC 13G/A, 2 filings Jun 22, 2022 to Feb 14, 2023³⁰

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
BML Capital Management, LLC	645,600	$5.0M	2.8%	No change
Vivo Capital, LLC	292,743	$2.3M	0.2%	No change
Kalehua Capital Management LLC	199,200	$1.5M	0.5%	−123,679
UBS Group AG	177,423	$1.4M	0.0%	+171,045
Vanguard Capital Management LLC	163,738	$1.3M	0.0%	−10,845
Millennium Management LLC	134,575	$1.0M	0.0%	+1,629
BlackRock, Inc.	55,504	$426.8K	0.0%	+3,486
Renaissance Technologies LLC	50,300	$386.8K	0.0%	−8,800
Nomura Asset Management International Inc.	50,000	$385.0K	0.0%	No change
Jacobs Levy Equity Management, Inc	43,051	$331.1K	0.0%	New
Geode Capital Management, LLC	42,234	$324.9K	0.0%	−6,777
LPL Financial LLC	32,075	$246.7K	0.0%	+12
Citadel Advisors LLC	30,639	$235.6K	0.0%	−7,923
Vanguard Fiduciary Trust Co	22,773	$175.1K	0.0%	+148
State Street Corp	17,595	$135.3K	0.0%	No change
Americana Partners, LLC	16,176	$124.4K	0.0%	No change
Dimensional Fund Advisors LP	15,761	$121.1K	0.0%	−4,214
Morgan Stanley	11,934	$91.8K	0.0%	−7,887
Vanguard Global Advisers, LLC	1,470	$11.3K	0.0%	No change
Northwestern Mutual Wealth Management Co	550	$4.2K	0.0%	New
International Assets Investment Management, LLC	125	$961	0.0%	New
Citigroup Inc	88	$677	0.0%	New
Tower Research Capital LLC (TRC)	32	$246	0.0%	New
Barclays PLC	29	$223	0.0%	−4,106
Bnp Paribas Financial Markets	7	$54	0.0%	No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARInstil Bio, Inc. filings on SEC EDGAR
2
GLEIFInstil Bio, Inc. LEI record (529900HW1XOEQEVG5T88)
3
Yahoo FinanceTIL quote
4
SEC EDGARInstil Bio, Inc. filings on SEC EDGAR
5
SEC EDGARInstil Bio, Inc. annual report, Item 1 (Business)
6
SEC EDGARInstil Bio, Inc. 10-K for fiscal 2021
7
SEC EDGARInstil Bio, Inc. 10-K for fiscal 2021
8
SEC EDGARInstil Bio, Inc. 10-K for fiscal 2021
9
SEC EDGARInstil Bio, Inc. 10-Q for fiscal 2026
10
SEC EDGARInstil Bio, Inc. 10-Q for fiscal 2026
11
SEC EDGARInstil Bio, Inc. 10-K filed 2026-03-27: income statement
12
SEC EDGARBronson Crouch, Chief executive officer
13
SEC EDGARSandeep Laumas, Chief financial officer
14
SEC EDGARVijay Chiruvolu, Chief Technical Officer
15
SEC EDGARZachary Roberts, Chief Medical Officer
16
SEC EDGARGeorge Matcham, Board member
17
SEC EDGARGwendolyn Binder, Board member
18
SEC EDGARJack Nielsen, Board member
19
SEC EDGARNimish P. Shah, Board member
20
SEC EDGARR. Kent McGaughy Jr., Board member
21
SEC EDGARSumita Ray, General counsel
22
SEC EDGARBML Investment Partners, L.P. SCHEDULE 13G/A on Instil Bio, Inc.
23
SEC EDGARVivo Capital IX, LLC SCHEDULE 13G/A on Instil Bio, Inc.
24
SEC EDGARBoxer Capital Management, LLC SCHEDULE 13G/A on Instil Bio, Inc.
25
SEC EDGARPERCEPTIVE ADVISORS LLC SCHEDULE 13G/A on Instil Bio, Inc.
26
SEC EDGARVenrock Healthcare Capital Partners II, L.P. SC 13G/A on Instil Bio, Inc.
27
SEC EDGARCurative Ventures V LLC SC 13D/A on Instil Bio, Inc.
28
SEC EDGARBoxer Capital, LLC SC 13G on Instil Bio, Inc.
29
SEC EDGARFMR LLC SC 13G/A on Instil Bio, Inc.
30
SEC EDGARRA CAPITAL MANAGEMENT, L.P. SC 13G/A on Instil Bio, Inc.